Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) - Trial NCT03500562
Access comprehensive clinical trial information for NCT03500562 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Terminated. The study focuses on Chronic Hepatitis C. Target enrollment is 3 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
N/A
May 08, 2018
Mar 29, 2019
Primary Outcome
Number of adverse events (AEs),Number of serious adverse events (SAEs)
Summary
Study is a non-interventional, prospective, multicenter post marketing surveillance study to
 determine the safety of daclatasvir based therapy
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03500562
Non-Device Trial